Haptoglobin Subunit Angiogenesis Promotion via Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to promote angiogenesis, particularly in conditions like cardiovascular and myocardial infarction diseases, where enhanced blood vessel formation is needed to improve tissue recovery and oxygen delivery.
Innovation Solution
Administration of haptoglobin subunits, such as haptoglobin 1-1, 2-1, 2-2, α1, α2, or β subunits, obtained through purification, gene engineering, or chemical synthesis, which inhibit inflammatory responses and promote cell proliferation, facilitating angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used, then current treatment standards are maintained, but angiogenesis promotion is insufficient
Solution Approach 1:
The patent changes the molecular parameters of haptoglobin by creating subunits with specific amino acid sequences ( SEQ ID NOs: 1-3) that have modified disulfide bond formations. This parameter change enables the haptoglobin subunits to promote angiogenesis more effectively while reducing inflammatory responses, thereby resolving the contradiction between reliability of angiogenesis promotion and productivity of blood vessel formation.
Solution Approach 2:
The patent segments the haptoglobin protein into specific subunits (α1, α2, β) with distinct amino acid sequences. By isolating and purifying these specific subunits, the invention achieves more targeted and effective angiogenesis promotion compared to using intact haptoglobin, thus improving both the reliability and productivity of the therapeutic effect.
2Reliability
If haptoglobin subunits are administered, then angiogenesis is promoted and tissue recovery is enhanced, but inflammatory response may be triggered
Solution Approach 1:
The patent modifies the molecular parameters of haptoglobin through specific amino acid substitutions and disulfide bond reconfigurations in the subunits. These parameter changes alter the protein's biological activity to promote angiogenesis while reducing pro-inflammatory effects, thus resolving the contradiction between tissue recovery capability and inflammatory response.
Solution Approach 2:
The patent converts the potential harmful inflammatory response into a beneficial effect by carefully designing the haptoglobin subunits. The modified subunits exhibit enhanced anti-inflammatory properties while maintaining angiogenic activity, transforming the potential harm of haptoglobin administration into a beneficial therapeutic effect that promotes tissue recovery without triggering inflammation.
3Reliability
If haptoglobin subunits are purified or synthesized, then therapeutic effectiveness is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the haptoglobin protein into specific subunits with defined amino acid sequences, which simplifies the purification and synthesis processes. By working with discrete subunits rather than the complete protein, the manufacturing process becomes more controllable and scalable, reducing the complexity associated with producing therapeutic haptoglobin preparations.
Solution Approach 2:
The patent modifies the molecular parameters of haptoglobin by creating subunits with specific amino acid sequences and disulfide bond configurations. These parameter changes enable the use of simpler purification methods and more efficient synthesis protocols, thereby improving therapeutic effectiveness while reducing manufacturing complexity through standardized protein engineering approaches.
Data Source
AI summary
Provided is a method for promotion of angiogenesis, comprising: administering a haptoglobin subunit to a subject in need thereof. Also provided is a method for treating a disease related to defective angiogenesis, comprising: administering a haptoglobin subunit to a subject in need thereof. Further provided is a method for promotion of angiogenesis, comprising: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3. Additionally provided is a method for treating a disease related to defective angiogenesis, comprising: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3.